ARAV is a startup that aims to DX and automate construction sites by providing solutions that enable advanced functions to be attached to existing construction equipment.
The construction industry is a huge growth industry with a market size of over $4T globally and $1T in Asia. Despite this, Japan is experiencing a serious labour shortage, with only 16.6% of the workforce attracted to the industry compared to the number of job vacancies, and with approximately 35% of the workforce aged 55 and over and 11% aged 29 and under, the industry is ageing more rapidly than other industries.
This problem is expected to be solved by DX of construction equipment, but it is not technically easy to develop solutions that can respond quickly to diverse construction sites and diverse construction equipment. Even if this could be achieved by specialised systems and machines, the cost would be too expensive to imprement them to the site.
Therefore, ARAV provides an unique remote control system that can be operated in real-time via the internet. The remote control system can be retrofitted to existing construction machineries, regardless of model, and can be remotely operated from any laptop PC or smartphone with an internet connection.

Automation has traditionally been out of the reach for smaller companies due to the large space requirements, technical know-how and machines limited to being single fuctional.
Closer Robots, founded in November 2021 will change this, with automation in picking, packing and palletizing accessible to smaller food processing companies.
Machines are expected to replace almost half of the workforce in the global food manufacturing space, the market potential is enormous. According to reserach firm Globe Newswire, it predicts the total addressable market in 2028 to be 130 billion USD world-wide. Closer believes the market size can be even greater through horizontal expansion including cosmetics, pharmaceuticals and other consumer products.
Our service differentiates as it is compact, scalable to multi-task and simple to operate. The core competence lies in the robot control, AI image-processing and simple-to-use interface. Our business model is Robot-As-A-Service, offering monthly subscription starting from $3,000 a month. Team of talented developers allows to build key functions in-house, allowing for quick development period, scalable yet low-cost solutions for manufacturers of all sizes. Today the smartphone is more powerful than room-size IBM mainframes from the 1960’s. Closer hopes to become the smartphone of mobile robots in the manufacturing space.

INOPASE Inc. is a medical device company focusing on developing miniaturized closed-loop neuromodulation to cure neurological disease for better treatment, such as Epilepsy, Urinary Incontinence and Faecal Incontinence, which is different from conventional neuromodulation that only achieved symptom reduction. We have a patented wireless charging technology and closed-loop technology.
The closed-loop technology is a personalized treatment because the treatment effect (Nerve stimulation) is automatically regulated based on each patient’s nerve monitoring. This approach can achieve higher treatment outcome and patient comfort.

INOPASE has two product pipelines: Closed-loop Sacral Neuromodulation and Closed-loop Brain Neuromodulation.
Closed-loop Sacral Neuromodulation: We are developing the world only smallest and smartest implant device to cure Urinary Incontinence and Faecal Incontinence. Sacral Neuromodulation market is forecasted to reach 2.4 billion USD global market by 2026. INOPASE aims to launch the product in 2026 and forecasts to reach 300 million USD sales by 2030.

Closed-loop Brain Neuromodulation: We are developing the world only full brain electrode coverage (128 & 256 electrodes) and thinnest electrode (10µm thickness) to treat Epilepsy. The brain neuromodulation is forecasted to reach 3.4 billion USD by 2027.

Wastewater treatment for more than 10 million people in Japan depends on the purification process by an advanced septic tank. Advanced septic tanks (AST) and their proper maintenance are necessary for sustainable wastewater treatment in Japan. However, the majority of AST maintenance companies have big challenges: insufficient staff, inefficient work culture caused by paper-based administrative work, and technical difficulties in remote monitoring of ASTs. It is an urgent task to increase human and time efficiency in the operation of the AST maintenance company by the digitalization of their business, and to ensure that proper and sustainable maintenance reaches all ASTs.
We provide AST maintenance companies with an “automatic maintenance scheduling” based on sensored AST condition, an “operation assistance system” that digitalizes the administrative tasks, and a “visualization for AST condition”. Three services are geared by an IoT sensor newly developed for AST. By implementing these systems, maintenance companies can increase the number of ASTs maintained per unit of staff. Monetizing model is that the maintenance companies pay a sensor installation fee for each AST, a system installation fee, and system usage subscription fee.

OUI Inc. is a University-launched startup founded by the ophthalmologists. Nowadays, over 44 million people are blind and 2 billion populations has a visual impairment, and the economic loss is calculated over 5 trillion USD. The main cause of this world blindness can be treatable by sufficient diagnosis and treatment. However, due to the lack of medical devices, these numbers are gaining these days. To solve this word problem, we invented a smartphone attachment medical device named “Smart Eye Camera(SEC)” which has an equal function as a conventional slit-lamp microscope. SEC achieved to perform an ophthalmology diagnosis anywhere, anyone, and anytime. SEC has great potential in remote diagnosis and online consultation especially in developing countries in isolated places. Moreover, we are developing diagnostic artificial intelligence (AI) to develop a new style of ophthalmology diagnostic system. We just started this project in 2021, now we have over 20 partners, and over 100 SECs are installed worldwide to bring an ophthalmology diagnosis, especially in Africa, Southeast Asia, and Latin America to screen out the treatable eye disease and bring them to suitable ophthalmology partners. We aimed to reduce 50% of the world’s blindness by expanding SEC.

We aim for a society where people can do what they want as long as they wish to continue, which might be work, daily life or hobby.

Qolo is a University-originated startup with a core technology that enables people to stand up even if they have limited lower limb motor ability.

Being seated long time would cause functional problems such as you cannot reaching your hands and eyes to higher places as well as health problems.
Health problems, including pressure sore, bone demineralization and circular system, would shorten the length of a healthy life.

Qolo cares wide range of their journey which starts from wheelchair to back to life.
We support rehabilitation first, then back up their daily life later.
Rehabilitation products make standing rehabilitation efficient and encourage the improvement of motor function without physical overload on therapists.
Mobility products enable them to stand up and move in daily life scenes even if they could not recover enough.

We develop those models parallel and make it Japanese market available in 2023, then 2026 in the US.
We do update quickly our product in Japan first since both models are not considered medical devices.

Redge, Inc. aims to provide sustainable and safe medical care to all over the world with clinical engineer technology. Medical devices are essential equipment for treating the patient in a hospital. However, the medical device failures are frequently happened in developing countries, resulting medical accidents and threatened patient’s lives. It is cause of lack of maintenance and education of medical devices in local area. In Japan, clinical engineer, national license is dealing with medical device to maintain high quality medicine. Therefore, Redge, Inc. provides “CeTrax”, packaging system including medical device management and education based on Japanese clinical engineer knowledge and experience. For management part, we provide a simple system that combines cloud database computing and AI image recognition. It leads to forecast medical device failure and balance supply & demand consumable parts based on prediction the working rate of medical device. For education part, combination of hands-on training and video contents will expand local medical provider resources. CeTrax will improve the quality and safety of medical devices in developing countries.

Algal Bio Co., Ltd., a biotech startup, was established in March 2018 based upon 20 years of research results at the University of Tokyo. We possess around 3000 algae strains.These algae strains produce naturally occurring functional substances such as carotenoids, long chain unsaturated fatty acids , protein and oils. In addition to the strains isolated from the environment, these algae strains include strains obtained by mutation breeding with heavy ion-beam irradiation. The need for biologically-derived functional substances is increasing globally due to consumer health and natural orientation, the avoidance of genetic modification, and various regulations on chemically synthesized substances. Our algae strain does not use genetic recombination technology, so it can meet a wide range of needs. We can provide functional substance, functional foods (health foods and supplements), cosmetics, functional beverages, natural additives, medicines and biofuels, etc.